196 related articles for article (PubMed ID: 9073308)
1. Monitoring of methotrexate and 7-hydroxymethotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: relation to oral mucositis.
Albertioni F; Rask C; Schroeder H; Peterson C
Anticancer Drugs; 1997 Feb; 8(2):119-24. PubMed ID: 9073308
[TBL] [Abstract][Full Text] [Related]
2. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: relation to pharmacokinetic parameters of methotrexate.
Rask C; Albertioni F; Schrøder H; Peterson C
Pediatr Hematol Oncol; 1996; 13(4):359-67. PubMed ID: 8837142
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
[TBL] [Abstract][Full Text] [Related]
4. High-dose methotrexate in children with acute lymphoblastic leukemia: 7-hydroxymethotrexate systemic exposure and urinary concentrations at the steady state correlate well with those of methotrexate.
Chládková J; Hak J; Martínková J; Chládek J
Arzneimittelforschung; 2010; 60(12):769-75. PubMed ID: 21265469
[TBL] [Abstract][Full Text] [Related]
5. Oral mucositis and salivary methotrexate concentration in intermediate-dose methotrexate therapy for children with acute lymphoblastic leukemia.
Ishii E; Yamada S; Higuchi S; Honjo T; Igarashi H; Kanemitsu S; Kai T; Ueda K
Med Pediatr Oncol; 1989; 17(5):429-32. PubMed ID: 2796859
[TBL] [Abstract][Full Text] [Related]
6. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia--a logistic regression analysis.
Rask C; Albertioni F; Bentzen SM; Schroeder H; Peterson C
Acta Oncol; 1998; 37(3):277-84. PubMed ID: 9677100
[TBL] [Abstract][Full Text] [Related]
7. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
[TBL] [Abstract][Full Text] [Related]
8. [Clinical application of the simultaneous detection of methotrexate and 7-hydroxymethotrexate in the delayed elimination for pediatric acute lymphoblastic leukemia].
Luo GJ; Wang L; Hu GF; Li CB; Liu HX; Peng MT
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(25):1973-1978. PubMed ID: 32629599
[No Abstract] [Full Text] [Related]
9. Plasma 7-Hydroxymethotrexate Levels Versus Methotrexate to Predict Delayed Elimination in Children Receiving High-Dose Methotrexate.
Fabresse N; Devictor B; Pissier C; Chambost H; Lacarelle B; Michel G; Solas C
Ther Drug Monit; 2018 Feb; 40(1):76-83. PubMed ID: 29120974
[TBL] [Abstract][Full Text] [Related]
10. Interference of 7-hydroxymethotrexate with the determination of methotrexate in plasma samples from children with acute lymphoblastic leukemia employing routine clinical assays.
Fotoohi K; Skärby T; Söderhäll S; Peterson C; Albertioni F
J Chromatogr B Analyt Technol Biomed Life Sci; 2005 Mar; 817(2):139-44. PubMed ID: 15686977
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of 7-hydroxymethotrexate after high-dose methotrexate treatment.
Milano G; Thyss A; Renee N; Schneider M; Namer M; Boublil JL; Lalanne CM
Cancer Chemother Pharmacol; 1983; 11(1):29-32. PubMed ID: 6883624
[TBL] [Abstract][Full Text] [Related]
12. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
Joannon P; Oviedo I; Campbell M; Tordecilla J
Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
[TBL] [Abstract][Full Text] [Related]
13. Renal excretion and pharmacokinetics of methotrexate and 7-hydroxy-methotrexate following a 24-h high dose infusion of methotrexate in children.
Winograd B; Lippens RJ; Oosterbaan MJ; Dirks MJ; Vree TB; van der Kleijn E
Eur J Clin Pharmacol; 1986; 30(2):231-8. PubMed ID: 3709652
[TBL] [Abstract][Full Text] [Related]
14. Global methylation in relation to methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.
Oosterom N; Griffioen PH; den Hoed MAH; Pieters R; de Jonge R; Tissing WJE; van den Heuvel-Eibrink MM; Heil SG
PLoS One; 2018; 13(7):e0199574. PubMed ID: 29985926
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of clinical assays for measuring high-dose methotrexate in plasma.
Albertioni F; Rask C; Eksborg S; Poulsen JH; Pettersson B; Beck O; Schroeder H; Peterson C
Clin Chem; 1996 Jan; 42(1):39-44. PubMed ID: 8565230
[TBL] [Abstract][Full Text] [Related]
16. 7-Hydroxymethotrexate concentrations in serum and cerebrospinal fluid of children with acute lymphoblastic leukemia.
Borsi JD; Sagen E; Romslo I; Slørdal L; Moe PJ
Cancer Chemother Pharmacol; 1990; 27(2):164-7. PubMed ID: 2249335
[TBL] [Abstract][Full Text] [Related]
17. Association of plasma methotrexate, neutropenia, hepatic dysfunction, nausea/vomiting and oral mucositis in children with cancer.
Cheng KK
Eur J Cancer Care (Engl); 2008 May; 17(3):306-11. PubMed ID: 18419635
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate-induced oral mucositis and salivary methotrexate concentrations.
Oliff A; Bleyer WA; Poplack DG
Cancer Chemother Pharmacol; 1979; 2(3):225-6. PubMed ID: 313282
[TBL] [Abstract][Full Text] [Related]
19. Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia.
Sari NM; Rakhmilla LE; Bashari MH; Zazuli Z; Suryawan N; Susanah S; Reniarti L; Raspati H; Supriyadi E; Kaspers GJL; Idjradinata P
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2025-2031. PubMed ID: 34319023
[TBL] [Abstract][Full Text] [Related]
20. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
